Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Andtbacka on the OPTiM Results of T-VEC for Melanoma

Robert Andtbacka, MD
Published: Friday, Jun 30, 2017



Robert Andtbacka, MD, associate professor in the Division of Surgial Oncology, Department of Surgery at the University of Utah School of Medicine, discusses the long-term follow-up of overall survival data from the phase III OPTiM study of taglimogene laherparepvec (T-VEC) for patients with metastatic melanoma.

In the OPTiM trial, patients were randomized to receive T-VEC or a subcutaneous GM-CSF. The primary endpoint was durable response rate, which was reported previously, explains Andtbacka. Patients who received T-VEC acheieved a high durable response rate.

A secondary endpoint of this study was overall survival which was met in this patient population, states Andtbacka.

<<< View more from the European Post-Chicago Meeting


Robert Andtbacka, MD, associate professor in the Division of Surgial Oncology, Department of Surgery at the University of Utah School of Medicine, discusses the long-term follow-up of overall survival data from the phase III OPTiM study of taglimogene laherparepvec (T-VEC) for patients with metastatic melanoma.

In the OPTiM trial, patients were randomized to receive T-VEC or a subcutaneous GM-CSF. The primary endpoint was durable response rate, which was reported previously, explains Andtbacka. Patients who received T-VEC acheieved a high durable response rate.

A secondary endpoint of this study was overall survival which was met in this patient population, states Andtbacka.

<<< View more from the European Post-Chicago Meeting

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Evolving Roles for Targeted Melanoma Therapies: Assessing Rapid Progress in the Field and Looking Toward Future CombinationsFeb 28, 20191.5
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Publication Bottom Border
Border Publication
x